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Objectives We developed and internally validated a risk score to predict in-hospital stroke or death after carotid artery
stenting (CAS).
Background A tool that accurately assesses CAS risk could aid clinical decision making and improve patient selection.
Methods Patients undergoing CAS without acute evolving stroke from April 2005 through June 2011 as part of the NCDR
Carotid Artery Revascularization and Endarterectomy (CARE) Registry were included. In-hospital stroke or death
was modeled using logistic regression with 35 candidate variables. Internal validation was achieved with boot-
strapping, and model discrimination and calibration were assessed.
Results A total of 271 (2.4%) primary endpoint events occurred during 11,122 procedures. Independent predictors of
stroke or death included impending major surgery, previous stroke, age, symptomatic lesion, atrial fibrillation,
and absence of previous ipsilateral carotid endarterectomy. The model was well calibrated with moderate dis-
criminatory ability (C-statistic: 0.71) overall, and within symptomatic (C-statistic: 0.68) and asymptomatic
(C-statistic: 0.72) subgroups. The inclusion of available angiographic variables did not improve model perfor-
mance (C-statistic: 0.72, integrated discrimination improvement 0.001; p  0.21). The NCDR CAS score was
developed to support prospective risk quantification.
Conclusions The NCDR CAS score, comprising 6 clinical variables, predicts in-hospital S/D after CAS. This tool may be useful
to assist clinicians in evaluating optimal management, share more accurate pre-procedural risks with patients,
and improve patient selection for CAS. (J Am Coll Cardiol 2012;60:1617–22) © 2012 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.026Carotid endarterectomy (CEA) effectively reduces stroke
risk in symptomatic and asymptomatic patients with carotid
stenosis compared with medical therapy (1,2). Modern trials
have demonstrated similar composite outcomes with carotid
artery stenting (CAS) compared with CEA in standard and
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communicate these risks to pa-
tients. This transfer of knowl-
edge facilitates shared decision
making and permits selection of
the therapeutic strategy that is
most congruent with patient and
clinician expectations (7). With
carotid stenosis, developing a
more refined understanding of
patient risk is particularly critical
because some factors may in-
crease the risk of both CAS and
CEA, others may influence the
respective procedural risks in op-
posite directions, and some risk
factors may be modifiable (8).
Additionally, certain characteristics that influence outcomes
with CAS may be distinct from those with CEA, and it is
clear that CAS is not merely a safer, less invasive alternative
to CEA for all patients (3).
Previous studies reported the clinical and procedural
characteristics associated with adverse outcomes after CAS
(9), and risk scores derived from single-center populations
with a limited number of adverse events have been described
(10,11). At present, however, there are no existing predic-
tion models or risk scores that can be used to quantify the
risk of adverse events in a broad representative population of
patients undergoing CAS. Using data from the CARE
(Carotid Artery Revascularization and Endarterectomy)
Registry, we developed and validated a pre-procedural risk
model and created a simplified version to support clinical
use and prospective risk stratification.
Methods
Patient selection. The CARE Registry is part of the
National Cardiovascular Data Registry (NCDR) and enrolls
patients with carotid stenosis who have undergone revascu-
larization with either CEA or CAS (12). The registry was
created to monitor clinical practice, assess patient outcomes,
and provide a framework for quality improvement initia-
tives. As of August 2012, the registry included 13,613 CAS
procedures performed at 173 hospitals.
All patients undergoing CAS from April 2005 through
June 2011 were initially evaluated for inclusion in this
analysis. Those with acute evolving stroke were excluded.
The primary outcome of interest was the occurrence of
in-hospital stroke or death (S/D). Stroke was defined as a new
neurological deficit persisting for 24 h. All outcomes were
abstracted by trained data collectors using standardized defini-
tions. Quality checks were implemented before incorporation
of the data into the CARE Registry, and problems were
resolved by sites before submission.
Statistical analysis. For all patients, we examined a broad
Abbreviations
and Acronyms
CAS  carotid artery
stenting
CARE  Carotid Artery
Revascularization and
Endarterectomy
CEA  carotid
endarterectomy
CI  confidence interval
NCDR  National
Cardiovascular Data
Registry
OR  odds ratio
S/D  stroke or deathlist of 35 variables relating to sociodemographic character-istics, cardiovascular history, neurological history, and an-
giographic characteristics (Tables 1 and 2). We conducted
bivariate comparisons of characteristics of patients with and
without in-hospital S/D using chi-square tests for dichot-
omous variables and t tests for continuous variables. We
initially sought to develop 2 separate prediction models: one
incorporating only those characteristics known before an-
giography (clinical model) that could be used to risk-stratify
patients before the procedure and a second that included
additional variables gained at the time of angiography
relating to lesion characteristics (angiographic model).
We conducted multivariable logistic regression to gener-
ate prediction models for the primary endpoint of S/D
incorporating clinical variables. We then conducted step-
wise selection of variables using a criterion for retention of
p  0.05. To account for the possibility that risk factors for
/D had different effects in asymptomatic and symptomatic
atients, we included interaction terms for symptomatic
tatus and each of the variables that were included in the
elected clinical model. After fitting the model in the entire
ataset, we conducted internal validation by refitting the
odel in 1,000 bootstrap samples with replacement. This
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Characteristic
Stroke or
Death
(n  271)
No Stroke or
Death
(n  10,851) p Value
Age, yrs 76.4 8.5 70.5 10.5 0.001
Male, % 57.2 61.6 0.15
Body mass index, kg/m2 29.0 13.9 29.7 19.7 0.54
Caucasian, % 91.9 92.0 0.92
GFR 60 ml/min, % 51.1 39.5 0.001
Smoker, % 66.4 73.9 0.01
Hypertension, % 91.1 90.7 0.81
Dyslipidemia, % 86.0 87.4 0.49
Peripheral arterial disease, % 41.1 43.0 0.54
Diabetes, % 37.6 37.6 0.99
Chronic lung disease, % 22.5 28.5 0.03
Impending major surgery, % 6.6 3.6 0.01
Previous neck radiation, % 4.4 6.0 0.27
Previous neck surgery, % 4.8 6.0 0.42
Ischemic heart disease, % 51.3 56.6 0.08
History of heart failure, % 21.0 17.9 0.19
History of atrial fibrillation or flutter, % 19.9 12.2 0.001
Dementia, % 6.6 2.9 0.001
Previous ipsilateral CAS, % 1.5 3.4 0.09
Previous ipsilateral CEA, % 10.3 16.6 0.01
Previous TIA, % 42.4 31.6 0.001
Previous ischemic stroke, % 27.7 14.5 0.001
Pre-procedure NIH Stroke Scale score 0.9 2.4 0.7 2.2 0.29
Target vessel, right, % 46.1 48.6 0.43
Urgent cardiac surgery within 30 days, % 8.4 3.1 0.001
Target lesion symptomatic within past
6 months, %
54.2 40.0 0.001
Contralateral occlusion, % 7.4 10.7 0.08
Values are mean  SD or %.
CAS carotid artery stenting; CEA carotid endarterectomy; GFR glomerular filtration rate;
MI  myocardial infarction; NIH  National Institutes of Health; TIA  transient ischemic attack.
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October 23, 2012:1617–22 The NCDR CAS Risk Scoremethod of model validation has been found to have lower
variability and lower bias potential compared with tradi-
tional split-sample validation and k-fold cross-validation
(13). All measures of model performance were corrected for
optimism, and the final reported model was recalibrated
based on a “shrinkage” factor derived from the calibration
slope. To further assess model calibration, we fitted a
smoothed line showing the relationship between predicted
and observed risk of in-hospital S/D based on the final
model (14). We additionally performed validation of this
clinical model using a separate cohort of CAS procedures
performed from July 2011 through December 2011 (n 
1,544) within the CARE Registry, which became available
after development of the original model.
A second angiographic model including all potential
clinical and angiographic features was constructed in a
similar fashion. To test the incremental improvement that
angiographic variables added to prediction, we compared
C-statistics using methods by DeLong et al. (15) and
computed the integrated discrimination improvement (16).
To support routine clinical use, we developed a risk score
based on a points system with weights based on the
coefficients in the final clinical model (17). Predictive
Baseline Angiographic CharacteristicsTable 2 Baseline Angiographic Characteristics
Characteristic
Stroke or
Death
(n  271)
No Stroke or
Death
(n  10,851) p Value
Target lesion location, % 0.87
Isolated CCA 10.0 9.3
Isolated ICA 71.2 70.9
Bifurcation 18.8 19.8
Arch type, % 0.05
I 46.4 52.5
II 39.6 37.6
III 14.0 9.9
Visible thrombus present, % 4.9 3.0 0.09
Ulceration, % 27.0 28.5 0.58
Calcification, % 66.8 62.4 0.14
Lesion length, mm 22.1 10.9 19.6 10.1 0.001
Minimum luminal diameter, mm 1.9 1.9 1.8 2.01 0.41
Pre-procedure stenosis, % 84.4 11.4 84.3 10.8 0.91
Values are % or mean  SD.
CCA  common carotid artery; ICA  internal carotid artery.
Multivariate Predictors of In-Hospital Stroke orTable 3 Multivariate Predictors of In-Hospit
Variable Beta Co
Intercept 8.
Impending major surgery 0.
Previous stroke 0.
Age (per 10 yrs) 0.
Target lesion symptomatic within 6 months 0.
Atrial fibrillation or flutter 0.
Previous ipsilateral CEA 0.CEA  carotid endarterectomy; CI  confidence interval; OR  odds ratio; SEperformance of the risk score was then characterized using
discrimination and calibration.
We also generated 2 additional models with different
primary endpoints. The first used a primary endpoint of
in-hospital myocardial infarction, stroke, or death (major
adverse cardiac event), and the second used a primary
endpoint of in-hospital ipsilateral S/D. Finally, within the
CARE registry, 30-day outcomes are available in a subset of
patients. To assess the ability of our primary model to
predict 30-day S/D, we assessed the discrimination of our
model in this subset of patients. Values of p  0.05 (2 tailed)
were considered to indicate statistical significance. All statisti-
cal analyses were performed using SAS version 9.2 (SAS
Institute, Cary, North Carolina).
Results
A total of 271 (2.4%) primary endpoint events occurred
during 11,122 procedures. Stroke occurred in 242 patients
(2.2%), and death occurred in 52 patients (0.5%). Of the
242 strokes, 165 (68.2%) were in the ipsilateral carotid
territory, 32 (13.2%) were in the contralateral carotid
territory, and 45 (18.6%) were in the vertebrobasilar terri-
tory or the location was unknown.
Bivariate analysis. Bivariate analysis demonstrated indi-
viduals with S/D were older and more likely to have
upcoming cardiac or other major surgery. Patients with S/D
were more likely to have experienced previous neurological
events and more often had symptomatic target lesions.
Additionally, atrial fibrillation, smoking, renal impairment,
dementia, and chronic lung disease were more common in
the group with S/D (Table 1).
Clinical model. After multivariable regression, 6 variables
were retained to form the final clinical model: impending
major surgery (defined as cardiac, vascular, or other surgery
planned within 8 weeks); previous stroke; age; symptomatic
target lesion within the previous 6 months; atrial fibrillation;
and previous ipsilateral CEA (Table 3). The patient char-
acteristics most strongly associated with S/D were impend-
ing major surgery (OR: 2.20; 95% CI: 1.34 to 3.61) and
previous stroke (OR: 2.03; 95% CI: 1.53 to 2.70). Previous
ipsilateral CEA was associated with a reduced risk of S/D
(OR: 0.63; 95% CI: 0.42 to 0.94).This model was found to
have a C-statistic of 0.71 in the overall population and was
oke or Death
nt SE p Value OR (95% CI)
0.5104 0.0001 —
0.2532 0.0019 2.20 (1.34–3.61)
0.1442 0.0001 2.03 (1.53–2.70)
0.0060 0.0001 1.76 (1.55–2.01)
0.1286 0.0006 1.55 (1.21–2.00)
0.1577 0.0290 1.41 (1.04–1.92)
0.2027 0.0240 0.63 (0.42–0.94)Deathal Str
efficie
2358
7876
7096
5675
4402
3441
4585 standard error.
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alidation of this model in the separate population of
atients undergoing CAS from July 2011 through Decem-
er 2011 yielded similar performance characteristics (in-
ospital S/D C-statistic: 0.68; Hosmer-Lemeshow p 
.38. Model discrimination and calibration within the
symptomatic and symptomatic subgroups were similar to
hose observed in the overall population (C-statistic: 0.72;
osmer-Lemeshow p  0.83; C-statistic: 0.68, Hosmer-
emeshow p  0.67, respectively). The inclusion of inter-
ction terms did not improve model performance and were
hus excluded from the final model (data not shown).
dditional analyses. Among angiographic variables, only
esion length was a significant predictor of S/D (Table 2)
OR: 1.11; 95% CI: 1.05 to 1.17 per 5 mm additional
ength). The addition of this variable to the existing clinical
odel did not improve model performance (C-statistic
.72, integrated discrimination improvement 0.001; p 
.21). Similarly, compared with the clinical model, the
odels using major adverse cardiac events and ipsilateral
/D as primary endpoints had similar risk predictors and
erformance characteristics (data not shown).
eighted clinical model. Because the ORs of the 6
linical variables were disparate, a weighted points system
as ascribed to each variable based on the magnitude its
ffect to create a risk score (Table 4, Fig. 2A) (17). The
iscriminatory ability of the risk score was unchanged
C-statistic: 0.71). The risk score was then applied to the
ARE population with available 30-day outcomes data
n  8,550). The risk score had similar discriminatory
Figure 1 Observed Versus Predicted Probability
of In-hospital Stroke or Death
This calibration plot depicts observed (y-axis) versus predicted (x-axis) in-hospi-
tal stroke or death rates for patients undergoing carotid stenting. Differences
between observed and predicted event rates were small across all levels of
risk (Hosmer-Lemeshow p  0.51).bility in predicting 30-day events (C-statistic: 0.67) andas able to stratify patients into different levels of risk
Fig. 2B). Online Figure 1 demonstrates how the risk score
ay be applied to individual patients for clinical use.
iscussion
ithin a large representative population of patients under-
oing CAS in the United States, we developed and vali-
ated a risk score that predicts in-hospital S/D after carotid
NCDR CAS Risk Score SystemTable 4 NCDR CAS Risk Score System
Variable Point Value
Impending major surgery 3
Previous stroke 3
Target lesion symptomatic in previous 6 months 2
Atrial fibrillation or flutter 1
Age, yrs
50 0
50–59 2
60–69 4
70–79 6
80–89 8
90 10
Previous ipsilateral CEA 2
NCDR  National Cardiovascular Data Registry; other abbreviations as in Table 1.
Figure 2 Stroke or Death Rates
Based on Cumulative Risk Score
Observed stroke or death rates are shown as a function of cumulative risk
score point total for the in-hospital (A) and 30-day (B) periods. The dashed
lines (B) represent thresholds at which the cumulative point total exceeds 3%
and 6% 30-day event rates.
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October 23, 2012:1617–22 The NCDR CAS Risk Scorestenting. This model consists of a small number of readily
available pre-procedural clinical variables. Importantly, in
the subset of patients with 30-day outcome data available,
the model maintains its discriminatory ability. We demon-
strated that there is a broad distribution of procedural risk
among patients undergoing CAS, further emphasizing the
need for accurate risk stratification.
In an environment where 2 carotid revascularization
strategies each pose unique risks influenced by patient
characteristics, a schema for risk assessment is necessary to
assist patients in selecting the most appropriate therapy (7).
The NCDR CAS risk score may enable clinicians to
identify those patients at excessive risk of CAS so that
medical therapy or CEA may be offered as alternatives.
Similarly, in patients with prohibitive risk with CEA, this
risk score is helpful in identifying patients with acceptable
CAS risk.
Risk assessment. In accordance with previous observa-
tions, age, symptomatic status, and previous stroke each
independently increased risk in this analysis (8,18–20).
Similarly, previous CEA was found to be protective, which
also is consistent with published data (8). Atrial fibrillation
and impending major surgery have not been routinely
associated with increased risk after carotid stenting. Atrial
fibrillation is inherently associated with cardioembolic
stroke risk (21), and this risk may be higher periprocedurally
due to the need to discontinue oral anticoagulation to safely
perform invasive procedures. Impending major surgery
likely reflects selection of a uniquely higher risk patient
population because these are individuals receiving percuta-
neous carotid revascularization in preparation for major
cardiac, vascular, or other types of surgery. Dual antiplatelet
therapy may be prematurely discontinued in these individ-
uals in preparation for surgery, which may potentially
increase perioperative risk as well. Finally, selection bias may
prevent patients with impending major surgery from receiv-
ing CAS due to perceived excess risk, and some studies have
excluded patients with atrial fibrillation from trial partici-
pation (3).
Although many of the risk factors identified in this
analysis are nonmodifiable, it is conceivable that strategies
could be implemented to decrease CAS risk. As an example,
in patients with atrial fibrillation, more aggressive antico-
agulation bridging practices or stenting via alternative access
sites without warfarin discontinuation may reduce stroke
risk. Similarly, in those patients needing urgent surgery, use
of intravenous or reversible antiplatelet agents may pose less
risk for stent-related complications perioperatively.
For individuals wishing to use the NCDR CAS risk
score, the CAS acronym facilitates clinical use. The letters
of the CAS acronym correspond to each variable (previous
ipsilateral CEA, Age, Atrial fibrillation, impending major
Surgery, Symptomatic target lesion, previous Stroke), and
he letter position (C-1, A-2, S-3) identifies the number of
isk variables beginning with that letter.he NCDR CAS score in the context of historical risk
tratification. The CEA literature has traditionally re-
erred to patients as being either high or standard surgical
isk based on the presence of any number of risk factors
ncluding clinically significant cardiac disease, severe pul-
onary disease, contralateral occlusion, previous neck radi-
tion, laryngeal nerve palsy, post-CEA restenosis, and age
80 years (22). However, we believe that in the develop-
ent of the NCDR CAS score, we have created an
nstrument that can be used to more precisely quantify risk
n a fashion that accounts for the differential impact that risk
actors contribute, as well as the additive impact that
ultiple risk factors may impart. In addition, the creation of
his risk score allows clinicians to readily stratify patients
nto widely accepted risk categories, including those based
n cutoffs of 3% and 6% in asymptomatic and symptomatic
atients, respectively (Fig. 2B) (23).We would caution,
owever, that such risk categories were defined in an era
efore the aggressive use of antiplatelet and lipid-lowering
herapy and before the routine use of embolic protection
evices for CAS (24). Major adverse cardiac event rates with
AS are decreasing (18,25), and it is unclear whether these
istorical stratification criteria maintain merit with modern
evascularization techniques (26).
tudy limitations. Several limitations warrant discussion.
irst, prediction of S/D using this model is most applicable
o the in-hospital period only because 30-day outcome data
re not uniformly available for all participants in CARE.
econd, we did not adjust for all variables that influence
AS-related risk including embolic protection device use,
lter time, operator experience, and other patient- or
esion-specific characteristics (27–29). Most operators may,
n fact, not consider CAS for patients with complex arch
natomy or severe tortuosity. Additionally, the angiographic
nformation collected within the CARE registry is limited,
nd it is possible that angiographic variables not captured in
his registry are important predictors of outcomes. Finally,
he generated model has moderate discriminatory ability
C-statistic: 0.71) and is not meant to substitute for clinical
udgment.
onclusions
e developed and internally validated a simple, easy-to-use
isk score to predict in-hospital S/D after CAS. This model
ay provide valuable information about procedural risk for
atients considering this therapy. The application of this
ool into clinical practice has the potential to improve
utcomes by optimizing patient selection for this procedure.
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APPENDIX
For a figure demonstrating how the risk score may be applied to individual
patients for clinical use, please see the online version of this article.
